236 related articles for article (PubMed ID: 16940419)
61. p53 overexpression in myeloid leukemic disorders is associated with increased apoptosis of hematopoietic marrow cells and ineffective hematopoiesis.
Orazi A; Kahsai M; John K; Neiman RS
Mod Pathol; 1996 Jan; 9(1):48-52. PubMed ID: 8821956
[TBL] [Abstract][Full Text] [Related]
62. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
Pellagatti A; Jädersten M; Forsblom AM; Cattan H; Christensson B; Emanuelsson EK; Merup M; Nilsson L; Samuelsson J; Sander B; Wainscoat JS; Boultwood J; Hellström-Lindberg E
Proc Natl Acad Sci U S A; 2007 Jul; 104(27):11406-11. PubMed ID: 17576924
[TBL] [Abstract][Full Text] [Related]
63. Abnormalities of adherent layers grown from bone marrow of patients with myelodysplasia.
Tennant GB; Walsh V; Truran LN; Edwards P; Mills KI; Burnett AK
Br J Haematol; 2000 Dec; 111(3):853-62. PubMed ID: 11122147
[TBL] [Abstract][Full Text] [Related]
64. New therapeutics for myelodysplastic syndromes.
List AF
Leuk Res; 2012 Dec; 36(12):1470-4. PubMed ID: 22959510
[TBL] [Abstract][Full Text] [Related]
65. Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis.
Raza A; Mundle S; Iftikhar A; Gregory S; Marcus B; Khan Z; Alvi S; Shetty V; Dameron S; Wright V
Am J Hematol; 1995 Mar; 48(3):143-54. PubMed ID: 7864021
[TBL] [Abstract][Full Text] [Related]
66. Deregulation of microRNAs in myelodysplastic syndrome.
Rhyasen GW; Starczynowski DT
Leukemia; 2012 Jan; 26(1):13-22. PubMed ID: 21852786
[TBL] [Abstract][Full Text] [Related]
67. Telomerase activity in myelodysplastic syndromes.
Gürkan E; Tanriverdi K; Başlamişli F
Leuk Res; 2005 Oct; 29(10):1131-9. PubMed ID: 16111531
[TBL] [Abstract][Full Text] [Related]
68. [Pathogenesis of myelodysplastic syndromes by excessive mitochondrial fragmentation].
Hayashi Y
Rinsho Ketsueki; 2024; 65(4):249-254. PubMed ID: 38684435
[TBL] [Abstract][Full Text] [Related]
69. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
70. Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome.
Xu F; He Q; Li X; Chang CK; Wu LY; Zhang Z; Liu L; Shi WH; Zhu Y; Zhao YS; Gu SC; Fei CM; Guo J; Wu D; Zhou L
Sci Rep; 2014 Dec; 4():7310. PubMed ID: 25472472
[TBL] [Abstract][Full Text] [Related]
71. Apoptosis in relation to CD34 antigen expression in normal and myelodysplastic bone marrow.
Pecci A; Travaglino E; Klersy C; Invernizzi R
Acta Haematol; 2003; 109(1):29-34. PubMed ID: 12486320
[TBL] [Abstract][Full Text] [Related]
72. Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelodysplastic syndromes (MDS).
Kotsianidis I; Bouchliou I; Nakou E; Spanoudakis E; Margaritis D; Christophoridou AV; Anastasiades A; Tsigalou C; Bourikas G; Karadimitris A; Tsatalas C
Leukemia; 2009 Mar; 23(3):510-8. PubMed ID: 19020538
[TBL] [Abstract][Full Text] [Related]
73. Malignant hematopoietic cell lines: in vitro models for the study of myelodysplastic syndromes.
Drexler HG
Leuk Res; 2000 Feb; 24(2):109-15. PubMed ID: 10654445
[TBL] [Abstract][Full Text] [Related]
74. New approaches to the treatment of myelodysplasia.
List AF
Oncologist; 2002; 7 Suppl 1():39-49. PubMed ID: 11961208
[TBL] [Abstract][Full Text] [Related]
75. Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival.
Gupta P; Niehans GA; LeRoy SC; Gupta K; Morrison VA; Schultz C; Knapp DJ; Kratzke RA
Leukemia; 1999 Jan; 13(1):44-53. PubMed ID: 10049059
[TBL] [Abstract][Full Text] [Related]
76. Aclarubicin induces differentiation of leukemic progenitors in myelodysplastic syndrome cooperating with granulocyte colony-stimulating factor.
Akashi K; Eto T; Shibuya T; Shimoda K; Harada M; Niho Y
Leuk Res; 2000 Mar; 24(3):243-8. PubMed ID: 10739006
[TBL] [Abstract][Full Text] [Related]
77. Differential expression of AURKA and AURKB genes in bone marrow stromal mesenchymal cells of myelodysplastic syndrome: correlation with G-banding analysis and FISH.
Oliveira FM; Lucena-Araujo AR; Favarin Mdo C; Palma PV; Rego EM; Falcão RP; Covas DT; Fontes AM
Exp Hematol; 2013 Feb; 41(2):198-208. PubMed ID: 23092930
[TBL] [Abstract][Full Text] [Related]
78. The role of p38 mitogen-activated protein kinase in serum-induced leukemia inhibitory factor secretion by bone marrow stromal cells from pediatric myelodysplastic syndromes.
da Costa SV; Roela RA; Junqueira MS; Arantes C; Brentani MM
Leuk Res; 2010 Apr; 34(4):507-12. PubMed ID: 19913910
[TBL] [Abstract][Full Text] [Related]
79. Expressional changes of genes and miRNA in common megakaryocyte-erythroid progenitors from lower-risk myelodysplastic syndrome.
Maki K; Sasaki K; Nagata Y; Nagasawa F; Nakamura Y; Ogawa S; Mitani K
Int J Hematol; 2014 Oct; 100(4):361-9. PubMed ID: 25056847
[TBL] [Abstract][Full Text] [Related]
80. Toll-like receptor-4 is up-regulated in hematopoietic progenitor cells and contributes to increased apoptosis in myelodysplastic syndromes.
Maratheftis CI; Andreakos E; Moutsopoulos HM; Voulgarelis M
Clin Cancer Res; 2007 Feb; 13(4):1154-60. PubMed ID: 17317824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
